Key US Hire & Grant of Options

RNS Number : 2849Z
Byotrol PLC
14 December 2017
 

 

14th December, 2017

 

 

 

 Byotrol plc

('Byotrol', the 'Group' or the 'Company')

 

KEY US HIRE

AND GRANT OF SHARE OPTIONS

 

 

Byotrol plc the AIM listed anti-microbial technology company, is pleased to announce the appointment of sales and marketing leadership for its wholly-owned US subsidiary Byotrol, Inc.

 

Alex Espalin has been advising Byotrol for twelve months on its commercialisation efforts in the US and has been key to getting the Company positioned to launch its US EPA-approved long-lasting surface care formulation.  He has now joined the Company formally as VP Sales and Marketing, Byotrol Inc.

 

Alex brings to Byotrol broad marketing, branding, management and entrepreneurial expertise, gained over a twenty-year corporate and entrepreneurial career including roles at Coca-Cola, Disney and Kimberly-Clark, where he had oversight for multiple new product launches. 

 

Alex earned his Bachelor of Science degree from Cornell University, an MBA from the University of Michigan and a Masters Degree in economic development from Harvard University

 

Alex Espalin has today been awarded 5 million share options in Byotrol plc at 4p, representing 1.24% of Byotrol plc fully diluted share capital. These options mature in dates varying up to 7 years from grant and will vest in three tranches when Byotrol Inc achieves a successful consumer product launch and/or certain US sales and profitability targets.

 

 

 

David Traynor, Chief Executive of Byotrol, said:

 

"We are delighted that Alex has joined the Company. He is entrepreneurial by nature, has excellent experience across B2B and B2C and we believe will be pivotal in building a business of quality for Byotrol in the US." 

 

Enquiries:

 

Byotrol plc            

David Traynor - Chief Executive                                                       01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance                        020 7220 0500

Stephen Norcross/Richard Chambers - Corporate Broking

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

 

Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone. 

 

For more information, please go to www.byotrol.co.uk

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

        1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alex Espalin

        2. 

Reason for the Notification

a)

Position/status

PDMR

b)

Initial notification/Amendment

Initial

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

options over ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Award of Options to subscribe for Ordinary Shares

c)

Price(s) and volume(s)

Volume - 5,000,000

Exercise Price - 4 pence

d)

Aggregated information:

See 4c) above

e)

Date of the transaction

14 December 2017

f)

Place of the transaction

Outside of a trading venue

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUOSNRBVAUAAA
UK 100

Latest directors dealings